Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. Pricing proposals such as reference pricing/Most Favored Nations as they relate to access to plasma derived therapies.
2026 · 1st Quarter (Jan 1 - Mar 31)
PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Filed by PLASMA PROTEIN THERAPEUTICS ASSOCIATION.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Amendment
- Posted
- May 19, 2026
- Income
- Not reported
- Expenses
- $160,000.00
- Registrant
- PLASMA PROTEIN THERAPEUTICS ASSOCIATION
- Filing UUID
- 3639244b-441a-49a4-8cfd-14a78449182d
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and Alpha 1. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Issues relating to tariffs and the importation of plasma-derived medicines, plasma intermediates, and materials necessary to collect source plasma donations and manufacture plasma derived-medicines.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.